Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

Purpose Anaplastic lymphoma kinase (ALK) mutations occurs in approximately 3–5% of patients with non-small cell lung cancer (NSCLC). Pleural involvement/effusion is common in ALK-positive patients with NSCLC at baseline. The aim of the study was to evaluate the characteristics of ALK-positive patien...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of cancer research and clinical oncology 2023-11, Vol.149 (14), p.13271-13277
Main Authors:	Güner, Gürkan, Aktaş, Burak Yasin, Başal, Fatma Buğdaycı, Demirkazık, Ahmet, Gürsoy, Pınar, Demirci, Umut, Erman, Mustafa, Yumuk, Perran Fulden, Şenler, Filiz Çay, Çakar, Burcu, Çiçin, İrfan, Öztürk, Akın, Coşkun, Hasan Şenol, Çubukçu, Erdem, Işıkdoğan, Abdurrahman, Ölmez, Ömer Fatih, Tatlı, Ali Murat, Karaağaç, Mustafa, Şakalar, Teoman, Eralp, Yeşim, Korkmaz, Taner, Kılıçkap, Saadettin
Format:	Article
Language:	eng
Subjects:	Adenocarcinoma Cancer Research Effusion Hematology Internal Medicine Liver Lung cancer Lymphadenopathy Medicine Medicine & Public Health Metastases Metastasis Non-small cell lung carcinoma Oncology Protein-tyrosine kinase Small cell lung carcinoma
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Purpose Anaplastic lymphoma kinase (ALK) mutations occurs in approximately 3–5% of patients with non-small cell lung cancer (NSCLC). Pleural involvement/effusion is common in ALK-positive patients with NSCLC at baseline. The aim of the study was to evaluate the characteristics of ALK-positive patients who have Ple-I/E. Methods In this multicenter study, patients with ALK-positive NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median progression-free survival (PFS), and overall survival (OS) were evaluated in 362 ALK-positive patients with NSCLC. Results Of the patients, 198 (54.7%) were male. The median age at the time of diagnosis was 54 (range 21–85) years. All patients’ histology was adenocarcinoma (100%). At baseline, 57 (15.7%) patients had Ple-I/E. There was no association between Ple-I/E and gender, lung metastasis, or distant lymphadenopathy (LAP) metastasis. The frequencies of liver, brain, and bone metastases were significantly higher in ALK-positive patients without Ple-I/E compared to those with Ple-I/E (respectively 18.2% vs 4.8%, p = 0.008; 19.1% vs 4.8%, p = 0.001; 20.6% vs 8.9%, p = 0.002). The median PFS was longer in ALK-positive patients who had Ple-I/E (18.7 vs 10.6 months, p = 0.017). Similarly, the median OS was longer in ALK-positive patients who had Ple-I/E (44.6 vs 22.6 months, p = 0.051). Conclusion Brain, liver, and bone metastases were lower in ALK-positive patients with Ple-I/E. Patients presented with Ple-I/E were prone to have better PFS and OS.
ISSN:	0171-5216 1432-1335